Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer
OncoTargets and Therapy2014Vol. 7, pp. 1653–1653
Citations Over TimeTop 10% of 2014 papers
Zhehai Wang, Minmin Li, Jun Guo, Changzheng Li, Lin Liu, Huan Shi, Liyan Liu, Huihui Li, Chao Xie, Xia Zhang, Wenwen Sun, Shu Fang, Xiang Bi, Jie Liu
Abstract
For irinotecan-based regimens in metastatic colorectal cancer, the UGT1A1*28 and UGT1A1*6 locus mutations can be regarded as predictors for irinotecan-associated severe delayed diarrhea, whereas no association between UGT1A1 gene polymorphisms and severe neutropenia was observed. We also found that neither clinical response nor prognosis were significantly associated with UGT1A1 gene polymorphisms.
Related Papers
- → Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial(2010)52 cited
- → UGT1A1*28 Genotype Predicts Gastrointestinal Toxicity in Patients Treated With Intermediate-Dose Irinotecan(2009)34 cited
- → Sequence Effect of Irinotecan and Fluorouracil Treatment on Pharmacokinetics and Toxicity in Chemotherapy-Naive Metastatic Colorectal Cancer Patients(2001)56 cited
- Irinotecan and UFT/leucovorin in patients with advanced cancers.(2000)
- → Comprehensive genetic definition of susceptibility to toxic side effects of irinotecan in mice.(2015)